EC Number |
Recommended Name |
Application |
---|
1.4.3.22 | diamine oxidase |
diagnostics |
a research prototype ELISA is able to reliably and accurately quantify the human enzyme in different biological fluids. The potential of diamine oxidase as biomarker in various diseases can be evaluated |
1.4.3.25 | L-arginine oxidase |
diagnostics |
the R305E mutant enzyme is suitable for the determination of L-arginine. L-Arginine can be a medical biomarker because patients with argininemia or cancer show unusual concentrations of L-arginine in the blood |
1.4.4.2 | glycine dehydrogenase (aminomethyl-transferring) |
diagnostics |
expression of HIF-1alpha and glycine decarboxylase (GLDC) are associated with shorter tumor-related survival, although not independent from each other. The combination of GLDC and HIF-1alpha expression emerges as an independent prognostic factor in in early-stage lung non-small cell cancer (NSCC) |
1.4.4.2 | glycine dehydrogenase (aminomethyl-transferring) |
diagnostics |
high glycine decarboxylase expression is associated with poor prognosis and advanced stages of neuroblastoma. MYCN amplification is a biomarker for glycine decarboxylase-based therapeutic strategies against high-risk neuroblastoma |
1.5.1.5 | methylenetetrahydrofolate dehydrogenase (NADP+) |
diagnostics |
prognostic significance of MTHFD1 in head and neck squamous cell carcinoma (HNSCC) as well as the association between MTHFD1 and immune cell infiltration. MTHFD1 overexpression is closely correlated with unfavorable prognosis of HNSCC, and it might play an important role in modulating the tumor immune microenvironment |
1.5.1.17 | alanopine dehydrogenase |
diagnostics |
the significant positive relationship between exposure length and enzyme activity of ADH and strombine dehydrogenase, SDH, in Montipora capitata supports the implementation of these enzymes as biomarkers for rapid analysis of hypoxia-induced stress in corals |
1.5.1.22 | Strombine dehydrogenase |
diagnostics |
the significant positive relationship between exposure length and enzyme activity of alanopine dehydrogenase, ADH, and SDH in Montipora capitata supports the implementation of these enzymes as biomarkers for rapid analysis of hypoxia-induced stress in corals |
1.5.3.1 | sarcosine oxidase (formaldehyde-forming) |
diagnostics |
a photobioelectrochemical sensor based on CdSe/ZnS quantum dot and sarcosine oxidase is developed to determine sarcosine concentrations. The linear range is from 0.1 mM to 1 mM and the sensitivity depends on the number of immobilised enzyme layers.It is demonstrated that the [SOD/PAH]6-layer system is well suited for sensitive sarcosine detection. Sarcosine is an intermediate in the enzymatic analysis of creatinine, and thus, a sarcosine sensor can be beneficial for the diagnosis of kidney diseases |
1.5.3.1 | sarcosine oxidase (formaldehyde-forming) |
diagnostics |
developement of a simple and low cost electrochemical enzymatic biosensor for the determination of sarcosine in urine, based on the covalent immobilization of sarcosine oxidase, using N-ethyl-N-(3-dimethylaminopropyl) carbodiimide and N-hydroxysuccinimide, on the surface of the screen-printed carbon electrode.The biosensor presents high analytical performance features, such as large concentration linear range (10-100 nM), low detection limit (16 nM) and large storage stability (60 days). The biosensor is successfully applied to the analysis of sarcosine in synthetic urine samples |
1.5.3.1 | sarcosine oxidase (formaldehyde-forming) |
diagnostics |
sarcosine oxidase is an important diagnostic enzyme in the renal function examination |
1.5.8.4 | dimethylglycine dehydrogenase |
diagnostics |
the enzyme may be a valuable biomarker of hepatocellular carcinoma diagnosis |
1.6.2.2 | cytochrome-b5 reductase |
diagnostics |
potential use of the enzyme in diagnostic areas |
1.7.2.7 | hydrazine synthase |
diagnostics |
gene hzsA, encoding hydrazine synthase, is used as a biomarker for differentiation of biofilms and suspension, lab scale nitritation-anammox reactor with Kaldnes K1 carriers. Discrimination between Candidatus Brocadia fulgida and Candidatus Kuenenia stuttgartiensis based on hydrazine synthase subunit A (hzsA) |
1.8.1.4 | dihydrolipoyl dehydrogenase |
diagnostics |
Bacillus sphaericus DLD-diaphorase exhibits considerable potential to be used as a component of diagnostic tests for the quantification of metabolites |
1.8.3.2 | thiol oxidase |
diagnostics |
QSOX1 is a potential prognostic marker which may prove of use in the staging of breast tumours and the stratification of breast cancer patients |
1.8.3.2 | thiol oxidase |
diagnostics |
the expression of QSOX1 in neuroblastoma tumors may influence its clinical course because this protein is involved in processes such as the maturation of the extracellular matrix and the induction of apoptosis in these tumors. The enzyme can be used as a prognostic biomarker to help better discriminate among risk groups |
1.8.98.2 | sulfiredoxin |
diagnostics |
the lung cancer patients with high Srx levels have significantly shorter survival and those with high TXNDC5 levels have longer survival. Cellular levels of Srx and TXNDC5 may be useful as biomarkers to predict the survival of individuals with lung cancer |
1.11.1.B2 | chloride peroxidase (vanadium-containing) |
diagnostics |
the observed bactericidal and virucidal activity of the alkalophilic P395D/L241V/T343A mutant of vanadium chloroperoxidase is an important step forward in the application of this robust enzyme as a component in disinfection formulations |
1.11.1.6 | catalase |
diagnostics |
catalase activity is significantly higher in patients with renal cell carcinoma than in controls. The marker catalase might be potentially important as an additional biochemical tool for diagnosing renal cell carcinoma |
1.13.11.5 | homogentisate 1,2-dioxygenase |
diagnostics |
crude enzyme preparations can be used for a spectrophotometric method for routine, sensitive determination of homogentisate in human urine |
1.13.11.27 | 4-hydroxyphenylpyruvate dioxygenase |
diagnostics |
the enzyme can be used for enzyme-based sensors for monitoring herbicides used in agriculture, i.e. mesotrione. Compared to the standard sensors, biosensors have assorted advantages, such as practicality, quick response, low cost, and high sensitivity. A nanobiosensor is developed based on HPPD for mesotrione detection |
1.13.11.63 | beta-carotene 15,15'-dioxygenase |
diagnostics |
genotyping AI rams for c.196C-T can be used in selection against the yellow fat trait |
1.13.12.5 | Renilla-type luciferase |
diagnostics |
Renilla Luciferase (RLuc) is a blue light emitter protein which can be applied as a valuable tool in medical diagnosis |
1.13.12.5 | Renilla-type luciferase |
diagnostics |
the split Renilla luciferase complementation assay (SRLCA) is one of the techniques that detect protein-protein interactions. The SRLCA is based on the complementation of the LN and LC non-functional halves of Renilla luciferase fused to possibly interacting proteins which after interaction form a functional enzyme and emit luminescence. The SRLCA can specifically detect the BGLF4/Hsp90 interaction and provide a reference to develop inhibitors that disrupt the Epstein-Barr virus kinase BGLF4 and heat shock protein Hsp90 interaction |
1.13.12.5 | Renilla-type luciferase |
diagnostics |
the enzyme is a good research tool as a reporter protein and bioimaging probes, yielding blue light using the substrate coelenterazine. However the applications are limited since RLuc is unstable under various conditions |
1.13.12.6 | Cypridina-luciferin 2-monooxygenase |
diagnostics |
Cypridina luciferase is used as bioluminescence reporter enzyme in yeast, bacterial, and mammalian cell-based assays, enzyme activity is measured with a luminometer by addition of native or synthetic luciferin, also known as Vargulin, 0.5 microM in 10 mM Tris-HCl, pH 7.4 |
1.13.12.6 | Cypridina-luciferin 2-monooxygenase |
diagnostics |
far-red luminescence imaging technology to visualize tumor specific antigens on cell surfaces in vitro (human hepato-cellular carcinoma cell line Huh-7) and in living bodies (mice xenografted with human Delta-like protein-positive Huh-7 cells), based on a far-red fluorescent indocyanine derivative conjugated to biotinylated Cypridina luciferase linked to an anti-human Delta-like protein (Dlk-1) monoclonal antibody (embryonic antigens expressed on the surface of many cancer cells) via biotin-avidin interaction |
1.13.12.6 | Cypridina-luciferin 2-monooxygenase |
diagnostics |
labeling of prostaglandin E2 with the bioluminescent enzyme Cypridina luciferase linked to monoclonal anti-prostaglandin E2 antibody as enzyme-linked immunosorbent assay (ELISA) system, detection of 7.8-500 pg/ml prostaglandin E2 |
1.13.99.1 | inositol oxygenase |
diagnostics |
the kidney-specific protein myo-inositol oxygenase is a potential biomarker of acute kidney injury, AKI |
1.14.11.2 | procollagen-proline 4-dioxygenase |
diagnostics |
activation of NF-kappaB is observed in colon cancer. PHD3 appears to be a tumor suppressor in colorectal cancer cells that inhibits IKKbeta/NF-kappaB signaling. Determination of PHD3 status could aid targeted therapy selection for patients with colorectal tumors that have increased NF-kappaB activity |
1.14.11.2 | procollagen-proline 4-dioxygenase |
diagnostics |
the prolyl-4-hydroxylase alpha subunit 2 is a biomarker for breast cancer progression. Increased mRNA levels of P4HA2 correlate with poor clinical outcome in breast cancer patients, which is independent of estrogen receptor status |
1.14.11.4 | procollagen-lysine 5-dioxygenase |
diagnostics |
PLOD expression is associated with human breast cancer progression, PLOD2 expression is specifically prognostic in breast cancer |
1.14.11.4 | procollagen-lysine 5-dioxygenase |
diagnostics |
the expression level of the procollagen-lysine, 2-oxoglutarate 5-dioxygenase (PLOD) might become a novel biomarker for prognosis and is a potential target for individual treatment decisions in lower-grade glioma (LGG) |
1.14.11.16 | peptide-aspartate beta-dioxygenase |
diagnostics |
the enzyme may have utility as a prognostic biomarker in breast cancer |
1.14.11.18 | phytanoyl-CoA dioxygenase |
diagnostics |
assays for Refsums disease should not be based on PAHX activity alone. At least four different types of mutation cause loss of PAHX activity in vivo. Mutations to the peroxisomal targeting sequence do not affect catalytic function but probably affect targeting or degradation of the enzyme. A second group of mutations, including truncation and missense mutations, results in total loss of activity. A third group of mutations results in uncoupling of substrate oxidation from that of 2-oxoglutarate. A fourth group of mutations causes partial inactivation by hindering binding/utilization of the 2-oxoglutarate cosubstrate and/or iron(II) cofactor. From the therapeutic and biochemical view-point the latter two groups are particularly interesting since it may be possible to restore their activity with modified cosubstrates |
1.14.11.18 | phytanoyl-CoA dioxygenase |
diagnostics |
the substrate phytanoyl-CoA is difficult to handle because of its amphipathic properties. Commercially available alternative substrates, such as hexadecanoyl-CoA or isovaleryl-CoA are potentially usefull |
1.14.13.1 | salicylate 1-monooxygenase |
diagnostics |
usage of the enzyme in a fluorescence assay that detects 3-hydroxybutyrate and cholesterol in the nanomolar range and is more sensitive than the current SHL-dehydrogenase amperometric sensors, making it applicable to the construction of a fiber-optic fluorescence biosensor for clinical diagnostic uses |
1.14.13.9 | kynurenine 3-monooxygenase |
diagnostics |
the upregulation of KMO currently serves as an independent prognostic biomarker to identify certain liver malignancies, particularly hepatocellular carcinoma (HCC). HCC patients who express increased KMO activity are known to have unfavorable clinical outcomes compared to those who do not. The upregulation of KMO also plays a critical role in triple-negative breast cancer progression and metastasis. The pharmacological inhibition of KMO with GSK180 granted therapeutic protection in acute pancreatitis rodent models preventing multiple organ failures |
1.14.14.3 | bacterial luciferase |
diagnostics |
expression of the bacterial luciferase system in mammalian cells for generation of bioreporters for in vivo monitoring and diagnostics technology, method evaluation and optimization, overview |
1.14.16.2 | tyrosine 3-monooxygenase |
diagnostics |
tyrosine hydroxylase is frequently used as a marker of dopaminergic neuronal loss in animal models of Parkinsons disease |
1.14.17.1 | dopamine beta-monooxygenase |
diagnostics |
genotype-controlled measurement of plasma DBH activity might be used as a potential biological marker of the response to trauma |
1.14.19.3 | acyl-CoA 6-desaturase |
diagnostics |
higher delta-6-desaturase activity is associated with a higher risk of developing metabolic syndrome |
1.14.19.30 | acyl-lipid (8-3)-desaturase |
diagnostics |
a higher serum concentration of the n-6 polyunsaturated fatty acid dihomo-gamma-linoleic acid and lower DELTA5-desaturase activity are associated with an increased risk of type 2 diabetes, independent of BMI, in Japanese adults |
1.14.19.30 | acyl-lipid (8-3)-desaturase |
diagnostics |
higher serum total n-6 polyunsaturated fatty acids, linoleic acid and arachidonic acid concentrations and delta-5-desaturase activity are associated with a lower risk of developing metabolic syndrome |
1.14.99.66 | [histone H3]-N6,N6-dimethyl-L-lysine4 FAD-dependent demethylase |
diagnostics |
dimethylation of histone H3 at lysine 4 in combination with trimethylation of histone H3 at lysine 4 is associated with an activated transcriptional state. An increase of H3K4diMe in neoplastic tissues is predictive of clinical outcome. In particular, tumor recurrence occurs earlier in low-grade prostate carcinoma patients with low H3K4diMe, independently of other clinical and pathologic parameters. Similarly, in large cell and squamous cell carcinomas, low H3K4diMe expression correlates with short survival |
1.15.1.1 | superoxide dismutase |
diagnostics |
Cu,Zn-SOD is a urinary marker of hepatic necrosis, but not hepatic fibrosis, overview |
1.15.1.1 | superoxide dismutase |
diagnostics |
the enzyme might be used to develop a biosensor for the detection of antioxidants and free radical activity |
1.15.1.1 | superoxide dismutase |
diagnostics |
Cu/Zn-SOD might be used as a bioindicator of the aquatic environmental pollution and cellular stress in pearl oyster |
1.15.1.1 | superoxide dismutase |
diagnostics |
the SOD in the cosmopolitan sponge Cliona celata is described as a useful biomarker for marine pollution in other marine invertebrates |
1.15.1.1 | superoxide dismutase |
diagnostics |
the variations of SOD expression pattern in yrtilus. edulis can be used as a tool for the marine environment monitoring |
1.16.1.8 | [methionine synthase] reductase |
diagnostics |
the MTRR A66G polymorphism is a potential biomarker for cancer risk |
1.17.3.2 | xanthine oxidase |
diagnostics |
the enzyme activity detection in sepsis can be used for a negative prognosis in sepsis diagnosis, overview |
1.21.1.1 | iodotyrosine deiodinase |
diagnostics |
improvement of pre-clinical detection of iodotyrosine deiodinase deficiency during the neonatal time |
2.1.1.1 | nicotinamide N-methyltransferase |
diagnostics |
high enzyme expression levels in oral squamous cell carcinoma cells indicates a favourable prognosis in patients, whereas the absence of NNMT expression constitutes a hallmark of aggressive biological behaviour |
2.1.1.1 | nicotinamide N-methyltransferase |
diagnostics |
NNMT is useful as a biomarker of lung cancer, stages I-III. The sensitivity of the detection in non-small cell lung cancer cells at 90% specficity increases from 25% to 32% when NNMT is used in combination with carcinoembryonic antigen, method development, overview |
2.1.1.1 | nicotinamide N-methyltransferase |
diagnostics |
the enzyme may serve as a potential biomarker for tumor diagnosis and a therapeutic target |
2.1.1.20 | glycine N-methyltransferase |
diagnostics |
enzyme level suitable as prognostic marker for human cholangiocarcinoma and hepatocellular carcinoma |
2.1.1.20 | glycine N-methyltransferase |
diagnostics |
partially suitable to distinguish between benign and malign tumor forms |
2.1.1.63 | methylated-DNA-[protein]-cysteine S-methyltransferase |
diagnostics |
introduction of the MS-MLPA assay may not only be helpful for predicting response of gliomas to temozolomide, but may also facilitate tailor-made treatment with other chemotherapeutic agents for a variety of tumors |
2.1.1.67 | thiopurine S-methyltransferase |
diagnostics |
the chip-based miniaturization provides a clinically feasible genotyping platform for one-at-a-time testing |
2.1.1.67 | thiopurine S-methyltransferase |
diagnostics |
thiopurine S-methyltransferase genotypes or phenotypes may be a predictive factor for azathioprine-induced toxicities |
2.1.1.310 | 25S rRNA (cytosine2870-C5)-methyltransferase |
diagnostics |
whereas protein p120 is almost undetectable in normal tissues, it is overexpressed in virtually all types of cancer cells and is therefore considered to be a predictive cancer marker |
2.1.2.2 | phosphoribosylglycinamide formyltransferase 1 |
diagnostics |
GART expression is associated with glioma grade and high GART protein expression might be related to poor outcome |
2.1.2.2 | phosphoribosylglycinamide formyltransferase 1 |
diagnostics |
increased expression of glycinamide ribonucleotide transformylase is associated with a poor prognosis in hepatocellular carcinoma |
2.1.2.3 | phosphoribosylaminoimidazolecarboxamide formyltransferase |
diagnostics |
enzyme variants are used to predict methotrexate response in juvenile idiopathic arthritis, overview |
2.1.3.1 | methylmalonyl-CoA carboxytransferase |
diagnostics |
monitoring propionibacteria population and propionic fermentation in human trials constitutes a crucial step in determining Propionibacterium freudenreichii ability to prevent intestinal disorders |
2.1.3.3 | ornithine carbamoyltransferase |
diagnostics |
the enzyme alone or in combination with other markers is a useful indicator for Kupffer cell activation as well as for mitochondrial damage in hepatic cells |
2.1.3.3 | ornithine carbamoyltransferase |
diagnostics |
ornithine carbamoyltransferase is one promising blood-based biomarker candidate for liver injury examination |
2.1.3.3 | ornithine carbamoyltransferase |
diagnostics |
the enzyme can be used as biomarker for early stage of hepatic injury induced by CCl4, diagnostics values are best in combination with total bile acid and phosphorylase measurements |
2.3.1.6 | choline O-acetyltransferase |
diagnostics |
ChAT is selected as a marker of cholinergicneurons. In the CA1 region of hippocampus of mice, several of the insulin signaling-related proteins are co-located with ChAT, and most double immunoreactive positive cells are pyramidal cells |
2.3.1.24 | sphingosine N-acyltransferase |
diagnostics |
important role for the CerS genes in breast cancer etiology or diagnosis, overview |
2.3.1.39 | [acyl-carrier-protein] S-malonyltransferase |
diagnostics |
coupled enzyme assay can be used in development and optimization of small-molecule inhibitors for antibacterial therapy |
2.3.1.B43 | protein-lysine desuccinylase (NAD+) |
diagnostics |
elevated SIRT5 expression in human breast tumors correlates with poor patient prognosis |
2.3.1.61 | dihydrolipoyllysine-residue succinyltransferase |
diagnostics |
the rSucB may be a candidate antigen for a specific serological diagnosis of Bartonella henselae infection |
2.3.1.135 | phosphatidylcholine-retinol O-acyltransferase |
diagnostics |
enzyme might be a prognostic or therapeutic marker in renal cancer |
2.3.1.135 | phosphatidylcholine-retinol O-acyltransferase |
diagnostics |
the Lrat knockout mutant mice may serve as animal model with early onset severe retinal dystrophy and severe retinyl ester deprivation |
2.3.1.189 | mycothiol synthase |
diagnostics |
the enzyme is a potential biomarker for direct diagnosis of tuberculosis using patient serum specimens |
2.3.1.261 | (4-hydroxyphenyl)alkanoate synthase |
diagnostics |
PCR-based enzyme expression analysis method development for the virulence marker gene pks15/1 in clinical isolates from sputum samples, overview |
2.3.1.297 | very-long-chain ceramide synthase |
diagnostics |
important role for the CerS genes in breast cancer etiology or diagnosis, overview |
2.3.2.2 | gamma-glutamyltransferase |
diagnostics |
direct detection of GGT activity can provide critical information for the diagnosis of several pathologies. Elevated serum GGT levels are a general marker of diseases affecting the liver |
2.3.2.2 | gamma-glutamyltransferase |
diagnostics |
the GGT enzyme is known as a diagnostic enzyme for liver and biliary related diseases |
2.3.2.13 | protein-glutamine gamma-glutamyltransferase |
diagnostics |
tTG is considered a prognostic marker for Parkinson's disease. tTG antibodies, and crosslinked gliadin, act as diagnostic tools in celiac disease |
2.3.2.23 | E2 ubiquitin-conjugating enzyme |
diagnostics |
ubiquitin-conjugating enzyme E2T is an independent prognostic factor and promotes gastric cancer progression |
2.3.2.24 | (E3-independent) E2 ubiquitin-conjugating enzyme |
diagnostics |
high expression of UBE2O is associated with low survival rate of gastric, lung, breast, and prostate cancer patients |
2.3.2.25 | N-terminal E2 ubiquitin-conjugating enzyme |
diagnostics |
UBE2W downregulation promotes cell apoptosis and correlates with hypospermatogenesis, which may be helpful for the diagnosis of male infertility |
2.4.1.14 | sucrose-phosphate synthase |
diagnostics |
sucrose phosphate synthase gene SPS is a suitable endogenous reference gene for genetically modified rice detection, method development and validation of the SPS gene as an endogenous reference gene and its optimized qualitative and quantitative PCR systems, overview |
2.4.1.17 | glucuronosyltransferase |
diagnostics |
3-epideacetycinobufagin can be used specially to measure the catalytic activity of UGT2B7 in biological samples due to its exclusive substrate specificty for the compound |
2.4.1.17 | glucuronosyltransferase |
diagnostics |
androgen glucuronidation by UGT2B17 is particularly interesting in doping control |
2.4.1.87 | N-acetyllactosaminide 3-alpha-galactosyltransferase |
diagnostics |
identification of N-acetyllactosamine moiety of glycoproteins and glycolipids by chemiluminescence with mutated enzymes |
2.4.1.102 | beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase |
diagnostics |
C2GnT1 might become a prognostic factor for endometrial carcinoma. Patients with C2GnT1 overexpression show significantly shorter survival, multivariable analysis also indicate that 2GnT1 overexpression is an independent prognostic factor |
2.4.1.102 | beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase |
diagnostics |
detection of core2 beta-1,6-N-acetylglucosaminyltransferase in post-digital rectal examination urine is a reliable indicator for extracapsular extension of prostate cancer. The number of GCNT1-positive cases is significantly lower in cases of organ-confined disease than in cases of extracapsular extension. GCNT1-negative tumors are a associated with significantly better prostate-specific antigen (PSA)-free survival compared with GCNT1-positive tumors. Multivariate analysis reveals that detection of GCNT1 expression is an independent risk factor for prostate-specific antigen recurrence |
2.4.1.102 | beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase |
diagnostics |
GCNT1 expression in prostate biopsy specimen is a significant and independent predictor of recurrence after radical prostatectomy, which can be used in pre-treatment decision making for the patient |
2.4.1.102 | beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase |
diagnostics |
possible role of GCNT3 gene expression as prognostic marker in colon cancer. Low CNT3 expression is a promising prognostic biomarker for colon cancer that could be used to identify early-stage colon cancer patients at high risk of relapse. The enzyme might also constitute a biomarker to monitor tumour response to chemotherapy in cancer patients |
2.4.1.102 | beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase |
diagnostics |
GCNT3 might be an essential glycosylation-related molecule in colorectal cancer and epithelial ovarian cancer progression, with potential interest as a predictive biomarker of response to chemotherapy. GCNT3 high-expressing Stage III-IV EOC patients have better response to conventional treatment and clinical outcome. Clinical relevance of GCNT3 expression in epithelial ovarian cancer (EOC), role of GCNT3 as a biomarker for cancer patients, overview |
2.4.1.109 | dolichyl-phosphate-mannose-protein mannosyltransferase |
diagnostics |
analysis of fibroblasts to elucidate the phenotypes of POMT1 mutations |
2.4.1.122 | N-acetylgalactosaminide beta-1,3-galactosyltransferase |
diagnostics |
C1GALT1 predicts poor prognosis and is a potential therapeutic target in head and neck cancer |
2.4.1.144 | beta-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase |
diagnostics |
GnT-III expression levels are elevated in high-grade serous ovarian carcinoma tissues and correlate with reduced survival |
2.4.1.149 | N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase |
diagnostics |
high expression of B3GNT3 is associated with unfavourable disease-free survival and overall survival in NSCLC patients, suggesting that B3GNT3 might be a potential prognostic biomarker for non-small cell lung cancer (NSCLC). B3GNT3 expression is an independent prognostic factor |
2.4.1.150 | N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase |
diagnostics |
GCNT2 is a regulator of epithelial-mesenchymal transition (EMT) and a candidate prognostic indicator of outcome in esophageal squamous cell carcinoma (ESCC) patients |
2.4.1.150 | N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase |
diagnostics |
GCNT3 might be an essential glycosylation-related molecule in colorectal cancer and epithelial ovarian cancer progression, with potential interest as a predictive biomarker of response to chemotherapy. GCNT3 high-expressing Stage III-IV EOC patients have better response to conventional treatment and clinical outcome. Clinical relevance of GCNT3 expression in epithelial ovarian cancer (EOC), role of GCNT3 as a biomarker for cancer patients, overview |